Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study

…, K Nakano, T Shimizu, J Tomomatsu… - Cancer …, 2021 - Wiley Online Library
Milademetan (DS‐3032, RAIN‐32) is an orally available mouse double minute 2 (MDM2)
antagonist with potential antineoplastic activity owing to increase in p53 activity through …

[HTML][HTML] Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma

…, K Nakano, M Yunokawa, M Ono, J Tomomatsu… - Modern Pathology, 2021 - Elsevier
Neuroendocrine carcinoma (NEC) of the head and neck is a rare type of malignancy,
accounting for only 0.3% of all head and neck cancers, and its clinicopathological and genomic …

Sequential analysis of neutrophil-to-lymphocyte ratio for differentiated thyroid cancer patients treated with lenvatinib

…, M Nishizawa, M Yunokawa, M Ono, J Tomomatsu… - in vivo, 2020 - iv.iiarjournals.org
Background/Aim: Neutrophil-to-lymphocyte ratio (NLR) has been reported to be associated
with poor prognosis for radioactive iodine ablation refractory differentiated thyroid cancer (RR…

Efficacy of paclitaxel-based chemotherapy after progression on nivolumab for head and neck cancer

…, T Urasaki, A Ohmoto, K Nakano, M Ono, J Tomomatsu… - in vivo, 2021 - iv.iiarjournals.org
Background/Aim: In the CheckMate-141 trial regarding head and neck cancer (HNC),
nivolumab conferred a survival benefit to patients. However, the best treatment sequence of …

[HTML][HTML] Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis

K Nakano, N Motoi, J Tomomatsu, T Gokita, K Ae… - BMC cancer, 2016 - Springer
Background After the approval of pazopanib for the treatment of soft tissue sarcoma (STS),
pneumothorax was reported as an unexpected adverse event during pazopanib treatment. …

Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib

…, Y Sato, K Nakano, M Yunokawa, M Ono, J Tomomatsu… - in vivo, 2020 - iv.iiarjournals.org
Background/Aim: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer
(ATC). However, tumor markers for ATC treated with lenvatinib is lacking. The aim of this …

[HTML][HTML] Pre-treatment neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of pazopanib treatment for soft-tissue sarcoma

…, N Hayashi, M Yunokawa, M Ono, J Tomomatsu… - Cancers, 2021 - mdpi.com
Simple Summary Second-line systematic therapy options for soft-tissue sarcoma (STS)
have remained unchanged for decades due to the rarity and various histological types …

[HTML][HTML] Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors

T Doi, Y Fujiwara, N Matsubara, J Tomomatsu… - Cancer Chemotherapy …, 2019 - Springer
Purpose Ipatasertib is a selective inhibitor of Akt, a frequently activated protein kinase in
human cancers. The current study assessed the safety, tolerability, and pharmacokinetics of …

Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor‐positive advanced breast cancer

…, T Kobayashi, K Nakano, J Tomomatsu… - Cancer …, 2018 - Wiley Online Library
Taselisib is a potent and selective phosphatidylinositide 3‐kinase ( PI 3K) inhibitor. The
present article reports the first study of taselisib administration in Japanese patients. The aim of …

A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma

K Nakano, S Marshall, S Taira, Y Sato, J Tomomatsu… - Oral oncology, 2017 - Elsevier
Background The effectiveness of the combination chemotherapy of weekly paclitaxel and
cetuximab has not yet been compared to that of the current standard regimen, EXTREME (…